The U.S. contraceptive market size accounted for USD 10.8 billion in 2025 and is predicted to increase from USD 11.52 billion in 2026 to approximately USD 20.66 billion by 2035, expanding at a CAGR of 6.7% from 2026 to 2035. Increased demand in the contraceptive market, speedy cultural change, political orientation, or socioeconomic pressure drives the growth of the U.S. contraceptive market.
Market at a Glance
Contraception is the work for preventing pregnancy. This can be a tool, a medication, a technology, or a behaviour. Contraception enables a woman to control her reproductive health and affords women the capability to be an active participant in their family planning. Contraceptive procedures are technical advances planned to overcome biology. Healthcare tools used to prevent pregnancy involve intrauterine devices or subdermal implants. The intrauterine device may or may not comprise progesterone, and the subdermal inserts contain progesterone. These tools are generally referred to as long-acting reversible contraceptives or LARCs.
What are the Market’s Growth Opportunities?
Recent developments in extended and continuous cycle oral contraceptive pills (OCPs) have shifted from simply preventing pregnancy to enhancing quality of life by lowering or removing menstruation. Extended-cycle levonorgestrel contraceptives are specifically valuable for women who intend less frequent withdrawal bleeding. An increasing number of women prefer extended-cycle pills that permit them to skip stages for three to twelve months. Lowers menstrual distress and symptoms related to PMS.
Most Common Contraceptive Methods Used in the U.S
| Contraceptive Methods | Percentages |
| Female Sterilization | 11.5% |
| Oral Contraceptive Pills | 11.4% |
| Long-acting Reversible Contraceptives | 10.5% |
| Male Condom | 7.1% |
Market Segmentation Overview
- By product type, the hormonal contraceptives segment contributed the largest market share of 42% in 2025. It lowers the menstrual cramping and bleeding, which in turn lowers the risk of developing anemia. Reduced pain throughout ovulation and reduced the challenges of pelvic inflammatory disease (PID). It reduced the challenges of fibrocystic breast changes. Reducing the risk of ectopic pregnancy, where an egg is produced outside the uterus.
- By gender, the female segment contributed the largest market share of 78% in 2025. Female contraceptives provide highly effective pregnancy prevention while offering noteworthy health benefits, with lower menstrual cramps, lighter periods, acne management, and reduced risks of ovarian and endometrial tumours. It reduces the risk of endometrial and ovarian cancer and protects against acute pelvic inflammatory disease and ectopic pregnancies.
- By distribution channel, the retail pharmacies segment contributed the largest market share of 34% in 2025, as these pharmacies offer numerous benefits for patients. Their acquaintance enables contented interactions, encouraging patient compliance. They often provide an extensive selection of medicines and supplementary medical care products, addressing various healthcare needs.
- By end user, the clinics segment contributed the largest market share of 40% in 2025. Clinics offer expert contraceptive counselling to support patients in selecting methods that best fit their lifestyle, healthcare history, and upcoming family goals. Many clinics offer STI and HIV testing and treatment as part of a standard visit, which is significant for long-term reproductive health.
Top Companies in the U.S. Contraceptive Market
The Cooper Companies is a significant player in IUDs, precisely distributing ParaGard, a non-hormonal copper IUD. Pfizer Inc. produces various hormonal contraceptive tools. Perrigo's Opill has become a main disruptor as the first daily OTC birth control pill available in US retail pharmacies. Organon & Co. significantly focuses on women's health, managing the prevalent Nexplanon implant and NuvaRing. Bayer AG provides significant contraceptive products such as Mirena IUD and the Skyla hormonal system.
Segments Covered in the Report
By Product Type
- Hormonal Contraceptives
- Oral Contraceptive Pills
- Injectable Contraceptives
- Transdermal Patches
- Vaginal Rings
- Barrier Methods
- Male Condoms
- Female Condoms
- Diaphragms
- Cervical Caps
- Long-Acting Reversible Contraceptives (LARC)
- Intrauterine Devices (IUDs)
- Permanent Methods
- Female Sterilization
- Male Sterilization (Vasectomy)
- Emergency Contraceptives
- Active Irrigation Sheaths
- Passive Irrigation Sheaths
By Gender
By Age Group
- 15–24 Years
- 25–34 Years
- 35–44 Years
- 45+ Years
By Distribution Channel
- Hospitals
- Clinics
- Homecare Settings
